Related Experiment Video
Updated: Apr 12, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
Lung cancer in the era of precision medicine
Katerina Politi1, Roy S Herbst2
1Department of Pathology, Yale University School of Medicine, New Haven, Connecticut. Department of Medicine (Section of Medical Oncology), Yale University School of Medicine, New Haven, Connecticut. Yale Cancer Center, New Haven, Connecticut. katerina.politi@yale.edu roy.herbst@yale.edu.
Abstract:
The past decade has been transformative for lung cancer patients, physicians, and scientists. The discovery of EGFR mutations that confer sensitivity to tyrosine kinase inhibitors in lung adenocarcinomas in 2004 heralded the beginning of the era of precision medicine for lung cancer. Indeed, it precipitated concerted efforts by many investigators to define molecular subgroups of lung cancer, characterize the genomic landscape of lung cancer subtypes, identify novel therapeutic targets, and define mechanisms of sensitivity and resistance to targeted therapies. The fruits of these efforts are visible every day now in lung cancer clinics: Patients receive molecular testing to determine whether their tumor harbors an actionable mutation, new and improved targeted therapies that can overcome resistance to first-generation drugs are in clinical trials, and drugs targeting the immune system are showing activity in patients. This extraordinary promise is tempered by the sobering fact that even the newest treatments for metastatic disease are rarely curative and are effective only in a small fraction of all patients. Ongoing and future efforts to find new vulnerabilities of lung cancers, unravel the complexity of drug resistance, increase the efficacy of immunotherapies, and perform biomarker-driven clinical trials are necessary to improve outcomes for patients with lung cancer.
Insights
Precision medicine has transformed lung cancer care, with targeted therapies and immunotherapies showing promise. However, challenges remain in overcoming drug resistance and improving curative outcomes for patients with metastatic lung cancer.
Area of Science:
- Oncology
- Genomics
- Precision Medicine
Background:
- The discovery of EGFR mutations in 2004 initiated precision medicine for lung cancer.
- Significant research has focused on molecular subgroups, genomic landscapes, and therapeutic targets.
- Advances include molecular testing, novel targeted therapies, and immunotherapies.
Purpose of the Study:
- To review the transformative impact of precision medicine on lung cancer treatment.
- To highlight progress in identifying molecular targets and understanding drug resistance.
- To outline future directions for improving patient outcomes.
Main Methods:
- Review of key discoveries and clinical advancements in lung cancer research over the past decade.
- Analysis of the integration of molecular testing and targeted therapies in clinical practice.
- Examination of the evolving landscape of immunotherapies and resistance mechanisms.
Main Results:
- Precision medicine, driven by molecular profiling, has led to targeted therapies and immunotherapies.
- New treatments show activity but are rarely curative for metastatic lung cancer.
- Understanding of sensitivity and resistance mechanisms has advanced significantly.
Conclusions:
- Precision medicine has revolutionized lung cancer care, offering new therapeutic avenues.
- Despite progress, significant challenges persist in achieving cures for metastatic disease.
- Future research must focus on novel vulnerabilities, resistance mechanisms, and biomarker-driven trials to improve patient outcomes.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:18Cancer